# 5-Amino-1MQ: What It Is **By TelosRX Editorial Team** ยท 2026-09-21 **5-Amino-1MQ is a small molecule studied for its effect on a metabolic enzyme called NNMT, and it is not currently offered by telos rx for compounding for patients today.** What to know 5-Amino-1MQ, short for 5-amino-1-methylquinolinium, is a small molecule that inhibits an enzyme called nicotinamide N-methyltransferase, or NNMT. Researchers have studied it mainly in animal models of obesity and metabolic dysfunction, with limited human data published so far. Telos rx does not currently offer 5-Amino-1MQ for compounding, because it remains under review as part of the broader research peptide category telos rx continues to evaluate. ## What NNMT actually does NNMT is an enzyme found mainly in fat and liver tissue. It uses up a molecule called SAM, short for S-adenosylmethionine, which cells rely on for many other metabolic reactions. When NNMT activity is high, researchers have observed that fat tissue tends to store energy rather than burn it, a pattern linked to obesity in animal studies. ## How 5-Amino-1MQ is thought to work 5-Amino-1MQ blocks NNMT activity in laboratory and animal studies. By reducing NNMT activity, the compound appears to shift cellular metabolism toward burning energy rather than storing it, based on the available preclinical research. You can read more about telos rx's current status on [5-Amino-1MQ](https://www.telosrx.com/pages/5-amino-1mq) directly, though telos rx does not currently offer this peptide for compounding. This mechanism is worth understanding on its own terms, separate from any claim about what it might do in a person rather than in a mouse. ## What the research actually shows so far Most of what is published about 5-Amino-1MQ comes from studies in mice fed a high fat diet. In that setting, researchers observed weight loss and improved markers of metabolic health over the treatment period compared to untreated animals. No large published human trials exist yet, so claims about how the compound behaves in people are extrapolated from animal data rather than confirmed directly. That gap between animal research and confirmed human outcomes is one of the central facts anyone researching this compound should keep in view. ## Why telos rx does not currently offer it Telos rx is reviewing 5-Amino-1MQ, along with a number of other research peptides, for possible inclusion in its compounding program. A 2026 committee review made non-binding recommendations regarding several research peptides. That is a recommendation, not a regulatory approval, and it has not changed what telos rx currently offers. Until that review concludes and regulatory status is clearer, 5-Amino-1MQ remains outside the current compounding program, with no confirmed date for when or whether that changes. ## Who tends to research this compound and why People researching 5-Amino-1MQ are often already familiar with metabolic health topics, sometimes from following GLP-1 medication or other weight-related research. The appeal is a mechanism that sounds different from appetite suppression, working instead on how fat cells handle energy at a cellular level. That is a meaningfully different proposed mechanism from a GLP-1 medication, which works primarily through appetite and digestion signaling rather than NNMT. Understanding that difference helps set realistic expectations about what any future 5-Amino-1MQ protocol might and might not do, if it becomes available. ## What kind of provider would ultimately evaluate this If 5-Amino-1MQ ever becomes part of a compounding program, the same kind of medical evaluation would apply to it. That is the same review already applied to every current telos rx protocol. That means a licensed provider reviewing your health history, screening for relevant conditions, and deciding whether a protocol makes sense for you specifically. This is different from a research chemical purchase, where no provider is involved in the decision at all, and the buyer bears the full weight of that gap. ## What a compounding pharmacy would need before offering this A compounding pharmacy cannot prepare a medication from raw material it cannot verify and source reliably at pharmaceutical grade. Beyond sourcing, a pharmacy needs a reasonable body of safety information to inform appropriate dosing and screening before offering a substance to patients. For 5-Amino-1MQ, that body of safety information is still developing, since most existing research has been conducted in animals rather than in controlled human studies. Those two requirements, reliable sourcing and adequate safety data, sit behind why telos rx has not added 5-Amino-1MQ to its compounding program yet. **Key takeaway:** 5-Amino-1MQ inhibits an enzyme called NNMT. It has shown effects in animal studies of obesity, but it lacks large published human trials and is not currently offered by telos rx for compounding today. ## How it differs from an approved metabolic medication Medications with FDA-approved indications for weight or metabolic health have gone through large controlled human trials before reaching patients. 5-Amino-1MQ has not gone through that process, and it is not FDA-approved for any use in people. Compounded medications in general are not FDA-approved either, but they are prepared from substances that meet specific regulatory criteria, which 5-Amino-1MQ does not currently meet at telos rx. ## How 5-Amino-1MQ is usually discussed alongside other research peptides Online discussions often group 5-Amino-1MQ with other metabolic and longevity peptides that share a similar research-stage status. That grouping is convenient for content and marketing, but it can flatten real differences between compounds with distinct mechanisms and distinct evidence bases. 5-Amino-1MQ's proposed mechanism, NNMT inhibition, is specific to it, and evaluating it on its own merits gives a clearer picture than treating it as interchangeable with unrelated peptides. That is part of why this article focuses narrowly on what is actually known about this one compound. ## How researchers measure the animal findings The most cited 5-Amino-1MQ studies used mice fed a diet designed to induce obesity, then treated with the compound over several weeks. Researchers tracked body weight, fasting blood sugar, and markers of fat tissue metabolism to see how treated animals compared to untreated controls. Those studies reported meaningful changes in the treated group, which is what has driven interest in the compound as a possible future metabolic tool. Animal studies are a standard early step in pharmacology research, but they do not confirm how a compound will behave in the more complex and varied biology of a person. ## The gap between a promising mechanism and an available treatment A compound can have a compelling proposed mechanism and still be years away from any confirmed human use. That gap is common across pharmacology research generally, not unique to 5-Amino-1MQ. Between early animal data and an available medical treatment sits a long list of steps: larger animal studies, safety testing, and typically controlled human trials. 5-Amino-1MQ has not completed that path, and no public information confirms when or whether it will. Reading about a mechanism is genuinely useful for understanding the science, but it is a different thing from reading about a treatment that is ready to use. ## Where this leaves someone interested in metabolic support today Telos rx currently offers four compounded peptide options for patients ready to start today. Those are [BPC-157](https://www.telosrx.com/pages/bpc-157), [PT-141](https://www.telosrx.com/pages/pt-141), [NAD+ nasal spray](https://www.telosrx.com/pages/nad-nasal-spray), and [sermorelin](https://www.telosrx.com/pages/sermorelin). NAD+ nasal spray supports cellular energy metabolism and is available today through telos rx's partner compounding pharmacies with asynchronous intake. [Start an online visit for NAD+](https://start.telosrx.com/start-online-visit/peptides) if cellular energy support is what drew you to read about 5-Amino-1MQ in the first place. That is a different mechanism from NNMT inhibition specifically, and any treatment remains subject to medical approval by a licensed provider. For background on NNMT and metabolic research, see the [NIH review of NNMT as a metabolic target](https://pmc.ncbi.nlm.nih.gov/articles/PMC11196770/). For how compounded medication is regulated, see the [FDA overview of drug compounding](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). ## Frequently Asked Questions ### What is 5-Amino-1MQ used for in research? Researchers have studied 5-Amino-1MQ mainly for its effect on NNMT, an enzyme linked to how fat tissue stores versus burns energy. Most published research involves animal models rather than people, so its eventual role in human treatment remains an open question. ### Does telos rx sell 5-Amino-1MQ? No. Telos rx does not currently offer 5-Amino-1MQ for compounding. It remains under review as part of the broader research peptide category, and adding it to the program is not confirmed or scheduled. ### Is 5-Amino-1MQ FDA-approved? No. It is not FDA-approved for any use in people, and no large published human trials currently exist. Most available evidence comes from laboratory and animal research, which is a meaningfully earlier stage of evidence than what supports an approved medication. ### What is NNMT and why does it matter? NNMT is an enzyme in fat and liver tissue that consumes a molecule called SAM. Higher NNMT activity has been linked to fat storage in animal studies, which is why inhibitors like 5-Amino-1MQ have drawn research interest from scientists studying metabolic health. ### Why is 5-Amino-1MQ not available if the research looks promising? Promising animal data is not the same as regulatory approval or a confirmed pharmacy sourcing pathway. Telos rx's review considers all of those factors together, not just published research results on their own, before any substance is added to the program. ### What should I do if I am interested in metabolic support now? Ask about NAD+ nasal spray, which telos rx currently offers as a compounded option that supports cellular energy metabolism through a different, already established mechanism worth discussing with a provider. _TelosRX is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations. This article is general information, not medical advice, and does not replace guidance from your own provider. TelosRX operates as an online-first, asynchronous telehealth service._ Questions about what telos rx currently offers today? Explore [telos rx's 5-Amino-1MQ page](https://www.telosrx.com/pages/5-amino-1mq) for its current status, or visit [telosrx.com](https://telosrx.com) to see the full current product lineup and what is available right now. --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/5-amino-1mq-what-it-is)